Breast cancer is certainly one of the leading causes of cancer-related deaths amongst women worldwide. Early detection is crucial for effective treatment and improved survival rates. In a groundbreaking move, Namida, a tear-based cancer screening company, has recently launched Auria, a revolutionary test that utilizes proteomics, or protein biomarkers, to detect breast abnormalities which will indicate the presence of breast cancer. This cutting-edge technology has the potential to rework breast cancer screening and improve outcomes for countless women.

Auria
Auria

“This is just not genetic testing,” says Omid Moghadam, CEO and co-founder of Namida. “Many ladies are accustomed to BRCA 1 and a couple of gene mutations, which result in an elevated risk of breast cancer. Nevertheless, eighty-nine percent of breast cancers should not hereditary. Auria tests what is definitely happening contained in the body at that moment.”

Tears, a biofluid with significant diagnostic potential, have long been ignored in the sector of cancer screening. Nevertheless, recent advancements in tear evaluation have opened up latest possibilities for noninvasive and accurate detection of varied diseases, including cancer. Namida has leveraged this potential to develop Auria, a state-of-the-art test specifically designed to discover breast abnormalities related to breast cancer.

“If we glance to ancient history, we are going to see the primary case documented of breast cancer within the daughter of Cyrus the Great,” says Moghadam. “The Greek surgeon felt the lump and removed the breast, and she or he was saved. This system, feeling for lumps, remained the one screening tool for breast cancer until the Eighties, when mammography was invented. Forty years later, mammograms are still the highest screening tool.”

This reality poses several problems for ladies. Firstly, mammography is an X-ray technique. Within the words of Moghadam, “One percent of breast cancer is brought on by overexposure to X-ray radiation. Mammography is the one type of screening that may actually provide you with cancer.”

A second danger of mammography doesn’t stem from the test itself, however the age of the tested patients. Current standards of care indicate mammography starting at ages 45 through 50, yet a recent study stated that half of breast cancer deaths are women under 45 years old. Months ago, the US Preventative Task Force really useful the screening age be moved to 40, but Moghadam and his team feel even 40 is simply too old.

“Breast cancers in women ages 30 through 40 are aggressive and sometimes fatal,” says Moghadam. “Early detection is significant. So many young women are contracting this and haven’t got a strategy to understand what is occurring to their bodies until it’s too late. To some, Auria offers peace of mind, and to others, it saves their life.”

The sensitivity and usefulness of mammography will also be called into query, as this relies entirely on the physiology of the breast, which differs from woman to woman. Dense and fibrous breasts don’t X-ray well; white calcifications wander away in a sea of white dense tissue readings. This truth brings light to an alarming reality: For 50 percent of girls, X-rays are useless and sometimes harmful, but they’re forced to undergo this testing before receiving alternative imaging.

That is where Auria is available in. With this easy and cost-effective solution, women of all ages and breast types can screen for protein biomarkers related to breast abnormalities without the usage of radiation. This test doesn’t require specialist training; it might probably be done in any lab, GP office, and even the comfort of 1’s home. This becomes a much simpler and quicker process, mirroring prostate cancer screening tests in men, which is completed at the first care level.

“Auria features a clinical consultation with a breast health specialist to review results and answer questions, empowering women with information through the first line of screening,” says Moghadam. “This changes the necessity and timing for the patient to determine a latest relationship with a specialist, a process so lengthy and expensive that around fifty percent of girls drop out.” Moghadam continues, “Our vision with Auria has all the time been testing that’s inexpensive and accessible.”

The testing process itself is easy and noninvasive. Patients provide a tear sample, which is then analyzed using advanced proteomic techniques. The test accurately measures the degrees of the identified biomarkers and compares them to established thresholds. Based on the outcomes, Auria can classify the presence of breast abnormalities and supply helpful information for further diagnosis and treatment.

Auria has proven to be effective and disruptive in additional ways than one, as evidenced by its recent Gold Edison Award for Innovation in Intelligent Diagnostics, winning over one other popular cancer screening test, Galleri by GRAIL. Backed by physicians and greater than a decade of research and clinical trials, Auria is being recognized for addressing the growing challenge of healthcare for ladies.

The launch of Auria marks a big advancement in the sector of breast cancer screening. By harnessing the ability of tear-based testing and protein biomarker evaluation, Namida has provided a breakthrough solution that provides noninvasive, early detection of breast abnormalities resulting in breast cancer. Auria has the potential to revolutionize the way in which breast cancer is diagnosed, improving survival rates and empowering women to take control of their health.